BPTH could be in for a bull market in 2025!One new low cap stock pick with my research described below, please do your own research aswell and remember these are risky moves - thus small allocation. I will be back with many crypto charts for next year as well, don't worry!
Bio-Path Holdings (BPTH) Overview: Bio-Path Holdings, Inc. is a biotechnology company focused on developing nucleic acid cancer drugs using its proprietary DNAbilize antisense RNAi nanoparticle technology. This technology allows for the development of drugs that can be administered through intravenous transfusion, targeting specific genes associated with cancer.
Last week, Bio-Path Holdings announced preclinical results for their drug candidate BP1001-A. The study demonstrated that BP1001-A enhances insulin sensitivity, suggesting its potential as a treatment for obesity in patients with Type 2 diabetes.
In 2025, Bio-Path Holdings plans to initiate a first-in-human Phase 1 clinical trial for BP1001-A, focusing on validating its safety, measuring pharmacokinetics, and establishing dosing for potential pivotal trials. This trial is aimed at further exploring BP1001-A's potential as a treatment for obesity and related metabolic diseases in patients with Type 2 diabetes.
A successful trial would likely lead to a significant increase in Bio-Path Holdings' stock price. The news of positive clinical results would be seen as a validation of the drug's potential, attracting more investor interest and possibly leading to partnerships or buyouts from larger pharmaceutical companies.
SPECULATION:
Estimating the yearly revenue potential and a fair valuation for Bio-Path Holdings (BPTH) based on BP1001-A's market entry involves several speculative assumptions, as we lack specific data on market penetration, pricing, competition, and long-term efficacy. Here's a theoretical breakdown:
Revenue Potential:
Market Size and Share:
Obesity and Type 2 Diabetes Market: The global market for treatments of obesity and Type 2 diabetes is substantial. For context, the global diabetes market alone was valued at approximately $51.1 billion in 2022, expected to reach $81.6 billion by 2030, growing at a CAGR of around 6.5% (). However, BP1001-A would be competing in a segment of this market focused on novel treatments or those with a unique mechanism like insulin sensitivity enhancement.
Assumed Market Share: Assuming BP1001-A captures a niche segment, let's speculate it achieves a 1% to 5% market share due to its novel mode of action and targeting a specific subset of Type 2 diabetes patients with obesity.
Pricing and Usage:
Drug Pricing: New diabetes drugs, especially those with innovative mechanisms, can be priced high. For instance, if we assume a yearly cost per patient of $10,000 (considering the high cost of biologics and similar therapies),
Patient Population: If we estimate that 1% of the diabetic population globally (approximately 537 million adults in 2021 according to IDF) could benefit from this drug, that's about 5.37 million patients. At 5% market share, this would mean 268,500 patients.
Revenue Calculation:
Annual Revenue: If 268,500 patients use BP1001-A at $10,000 per year, the potential annual revenue would be approximately $2.685 billion. For a 1% market share (53,700 patients), it would be around $537 million.
Valuation:
DCF Approach: A Discounted Cash Flow (DCF) analysis would be the traditional method to value BPTH if BP1001-A were to generate such revenues. Here's a simplified speculative approach:
Cash Flow: Assuming 50% of revenue translates into gross profit (considering R&D, marketing, and other costs), a 1% market share would yield $268.5 million in gross profit, and 5% would yield $1.3425 billion.
Discount Rate: Biotech companies often have high discount rates due to risk. Let's assume a 15% discount rate for this speculative valuation.
Growth & Terminal Value: Assume growth stabilizes after initial high growth years, with a terminal growth rate of 2% post-patent exclusivity period (which might be around 20 years from patent to market).
Valuation Calculation:
With a 1% market share scenario:
Present Value of Cash Flows for first 10 years (assuming rapid growth then stabilization): $268.5M * Annuity Factor at 15% = $1.4 billion (very roughly).
Terminal Value (Gordon Growth Model) = $268.5M * (1+0.02)/(0.15-0.02) = $2.14 billion.
Total Equity Value = PV of cash flows + Terminal Value = $3.54 billion.
With a 5% market share scenario:
Present Value of Cash Flows for first 10 years: $1.3425B * Annuity Factor at 15% = $7 billion (again, very roughly).
Terminal Value = $1.3425B * (1+0.02)/(0.15-0.02) = $10.7 billion.
Total Equity Value = $17.7 billion.
Market Multiples: If we use industry multiples (PE ratios for biotech can be very high, especially for novel treatments), with a PE ratio of 20-30 for a company with significant growth potential, the valuation based on earnings from BP1001-A alone would range from:
1% Market Share: $5.37 billion (20 * $268.5M) to $8.055 billion (30 * $268.5M).
5% Market Share: $26.85 billion (20 * $1.3425B) to $40.275 billion (30 * $1.3425B).
Fair Valuation:
Given these speculative numbers, a fair valuation for BPTH based solely on BP1001-A's potential would be somewhere in the middle of these ranges, adjusted for the company's current financials, other pipeline drugs, and market conditions. Considering the above, a conservative estimate might place BPTH's valuation in the range of $3 billion to $10 billion, depending on market penetration optimism, with the understanding that this is highly speculative and subject to countless variables including regulatory approval, actual market acceptance, and competitive landscape.
CONCLUSION & TA:
This simply means, IF(!) this drug is succesfull the market cap of this company would significantly rise. Currently we're sitting at a 5.43 million market cap (at close, so lower now), thus its a 100 to 1000x potential or it drops to zero. Last note, price needs to stay above $1 to stay compliant with Nasdaq rules or else there could be an inverse stock split 2 to 1 for example or they face delisting by the end of Q3 2025. I'm not too worried because this is the same as SEALSQ faced before it 10x'd in the last few weeks.
TA wise: we're retesting previous resistance and the bull market support band. Chart has been down only for years, capitulation after capitulation thus chance of a rebound should be there. I grabbed a small allocation to sit out for 2025, if the clinical trials are successful, we'll in for a big bull market. If not succesfull, we'll likely lose our money. A very decent risk / reward ratio of you invest an amount you can afford to lose and not more than 5% of your portfolio.
This is one of my low cap stock picks, next to LAES (10x since entry) and MOBX (entry last week, flat pa for now). I will be scouting for more but for now, happy holidays!
Mobixlabs
Mobix Labs is gearing up for a bull market!We're back with a new stonk after doing about a 7x on SEALSQ! I don't have much time to write an in depth analysis so please do your own research on this company.
Mobix Labs looks to be settling in their growth market, defense contracts signed and a possible acquisition. Earnings are TOMORROW Dec 19th, so of course this is risky - bad earnings could dump the stock significantly. If however, earnings are good and the investor call brings some good news, this one could fly. Technical breakout target is $10 and I like the nice retest on the bull market support band. $2.16 is the first resistance to break and to retest for a first move towards $3.5.
Let's see, remember these are low caps and risky!
MOBX resistance / support flip, target: +100% nextMobix Labs had volatile pa after earnings, an overreaction as revenue was up over 400% beating estimates. They're still at an operating loss, which is normal for a startup.
Story is simple, they did multiple acquisitions this year:
RaGE Systems:
Revenue for 2024: Not specified.
Acquisition Cost: Approximately $2 million in cash, $10 million in Mobix Labs stock, and possible earn-out payments up to $8 million over eight fiscal quarters.
Description: Provides radio frequency joint design and manufacturing services.
J-Mark Connectors Inc.:
Revenue for 2024: Not specified.
Acquisition Cost: Financial terms remain undisclosed.
Description: Specializes in custom interconnect solutions for industries like aerospace, military, and defense.
Spacecraft Components Corp.:
Revenue for 2024: Not specified, but 2023 unaudited revenues were $18.1 million with forecasted growth for the next two years.
Acquisition Cost: Between $18 million and $24 million, with consideration to be paid in a combination of cash and equity, subject to earnout provisions.
Description: Manufactures mission-critical electronics for the aerospace, defense, and transportation sectors.
Now especially Spacecraft Components Corp. is notably as they do 18.1 million in revenue and are worth roughly 22 million. Mobix Labs reported about 3 million in revenue yesterday.
This means they will do 7x the revenue after the acquisition is completed in Q1 2025. Next to that they secured the following contracts in 2024 that are not part of the current revenue:
In 2024, Mobix Labs, Inc. secured the following contracts:
M-1 Abrams Tank Army Contract: for filtered connectors.
Sole Source Supply Contract: with Gulfstream Aerospace Corp. for custom filtered connectors used in their business-jet aircraft.
GE HealthCare and PerkinElmer Contract: for the sale of proprietary electromagnetic filtering products used in pharmaceutical diagnostics and digital imaging solutions.
Tomahawk Missile System Contract: for filtered connector parts.
Javelin Missile System Contract: for guidance system components.
A 15-month Contract: to supply critical components for aerospace and defense applications, though specific details about the customer or components were not specified.
EMI Interconnect Solutions: announced new filtered ARINC connectors and secured aerospace customers.
These contracts span various sectors, focusing mainly on military, defense, aerospace, and medical applications.
---
Looks to me this company is undervalued and has a lot of growth ahead in 2025... I added on the dip and any buy under $2 should be good long term.
Short term pa looks like a support resistance flip and a next target of $3.52 - I also like that this stock isn't popular whatsoever, similar to LAES (SEALSQ) when I found it.
A patient hold for me, DYOR, happy holidays!
